I am afraid that SUPG's world revolves around Dacogen for investors and even worse Dr. Manuso is in denial.
Look, you do not have to attend Wharton to understand that one product just does not cut it. When will they get that? This guy just can not come through for the shareholders and that should be clear to everyone. If this stock stays below $2.00 and the BOD does not can him then SUPG is in big trouble. I have seen this before, when the pain becomes to much for the big stakeholders then you will see him gone. Regretably it will cost SUPG $$$ to "Outplace" him but the best we can hope for is the selection of a CEO who puts dealmaking above scientific conferences.
Actually, reading the responses to the ignored poster in our case here is pretty comical, because you get the underlying jist of what the doofball said, without having to read the ridiculousness of it all. :)
Congratulations on ignore Alph. However you've only evolved to the next level. Soon you will support my next upgrade to request from Yahoo. Be able to ignore posts that are responses to an ignored poster. Say "Rory" for example....; - )
Billy et al, ignore is a wonderful thing, believe me.
Best 2 days of posting for me on this board since I got here have been the 2 days since I've put that goof on ignore.
Highly recommended. :)
The last thing I want to see SUPG do,is try to make something happen, to overreact to the situation. I however, want them to have a back up plan, just in case data is poor. Companies try to buy their way out of a situation and usually pay way to much and end up in worst shape.
Here's what I WANT IN A SMALL BIO:
1. One approved drug
2. A growing pipeline
3. Strong cash position
4. Focused on providing unmet areas and emphasis on low toxicity
5. Early success in ph1
6. Compounds that cannot at the last minute show more negatives than positives
7. Next generation compounds
8. Continued identification of pipeline drugs
9. Conservative on the spending
10. Solid partners
To me it sounds like we have an CEO from Wharton, what we lack is the common sense that sometimes their are hiccups along the way. There are many more positives coming and this is a 2-4 year hold.
<<Look, you do not have to attend Wharton to understand that one product just does not cut it. When will they get that?>>
There you go again...
What do you wwant him to do? It takes years to get a pipeline compound to market. Do you want him to go out and buy a phase 3 drug when the pipeline is this strong?
>>Do you want him to go out and buy a phase 3 drug when the pipeline is this strong? <<
Noooooooo, don't do that! We need that warchest for our dividend... or share buyback! ;)
Hey Jelly, we may be crazy, but there are obviously some people around these parts who are just plain dumb. Personally, I prefer crazy. ;)
>>Look, you do not have to attend Wharton to understand that one product just does not cut it.<<
Uhm, 1 product is better than 0 (which is what many biotechs have - 0).
Is Manuso supposed to pull a compound out of his ass and toss it out on the market? How do you expect them to have "more than 1" drug, isn't that what the pipeline is for?
BTW - there are a number of profitable biotechs have only 1 major drug on the market and they've done very well over the years. Dacogen I don't believe is this drug for SUPG, but it's better than nothing.